论文部分内容阅读
研究背景:血液动力学显著改变的先天性心脏病(CHD)是幼儿重度呼吸道合胞病毒(RSV)性疾病的危险因素之一。要评估使用呼吸道合胞病毒单抗体palivizumab进行RSV免疫预防的潜在功效,需要获得CHD患者RSV住院率的群体数据。目的:①获取24个月龄以下CHD患儿RSV住院率的群体资料。②将CHD 患儿的结果与非CHD患儿以及既往研究结果进行对照研究。③呼吸道合胞病毒单抗体接种可用于预防RSV
Background: Hemodynamically significant congenital heart disease (CHD) is one of the risk factors for severe respiratory syncytial virus (RSV) in young children. To assess the potential efficacy of RSV immunoprophylaxis with the respiratory syncytial virus monoclonal antibody palivizumab, population data on the RSV hospitalization rate for CHD patients are needed. PURPOSE: To obtain population data of RSV hospitalization rate in CHD children under 24 months of age. ② The results of CHD children with non-CHD children and the results of previous studies were controlled. ③ respiratory syncytial virus monoclonal antibody vaccination can be used to prevent RSV